Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
There is an upward development for Pacira Pharmaceuticals compared to yesterday, with an increase of €0.40 (1.900%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on Pacira Pharmaceuticals.
With a target price of 29 € there is a positive potential of 35.51% for Pacira Pharmaceuticals compared to the current price of 21.4 €.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 1.900% | 4.902% | 4.902% | 14.439% | 15.676% | -49.528% | -53.275% |
| Twist Bioscience Corp | -2.080% | -5.009% | -4.111% | -41.759% | -42.357% | 8.611% | -77.470% |
| Rockwell Medical Inc. | -0.990% | -5.729% | -2.742% | -59.451% | -60.417% | -14.194% | -92.157% |
| Vericel Corp. | 0.000% | 1.935% | -10.734% | -42.018% | -42.018% | 42.471% | 39.514% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat